

Benjamin Mullish

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/622253/benjamin-mullish-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

2,334
citations

25
h-index

46
g-index

199
ext. papers

3,363
ext. citations

7.4
avg. IF

5.5
L-index

#	Paper	IF	Citations
110	Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections.. <i>Frontline Gastroenterology</i> , 2022 , 13, 86-88	2.6	1
109	Rapid resolution of COVID-19 after faecal microbiota transplantation. <i>Gut</i> , 2022 , 71, 230-232	19.2	15
108	The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases.. <i>Gut Microbes</i> , 2022 , 14, 2038856	8.8	5
107	Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome.. <i>BMC Gastroenterology</i> , 2022 , 22, 240	3	1
106	Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent <i>C. difficile</i> Infection. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1371-1378	4.5	14
105	The gut microbiome: what every gastroenterologist needs to know. <i>Frontline Gastroenterology</i> , 2021 , 12, 118-127	2.6	5
104	Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	5
103	A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Infection. <i>Cells</i> , 2021 , 10,	7.9	2
102	How to Adapt an Intestinal Microbiota Transplantation program to reduce the risk of invasive multidrug-resistant infection. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	1
101	: innovations in target discovery and potential for therapeutic success. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 1-15	6.4	2
100	Non-Alcoholic Fatty Liver Disease and Vascular Disease. <i>Current Vascular Pharmacology</i> , 2021 , 19, 269-279	3.3	6
99	Changes in IgA-targeted microbiota following fecal transplantation for recurrent infection. <i>Gut Microbes</i> , 2021 , 13, 1-12	8.8	5
98	Reply to Woodworth, et al. <i>Clinical Infectious Diseases</i> , 2021 , 72, e924-e925	11.6	1
97	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to <i>Clostridioides difficile</i> Infections into the Local Clinical Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021 , 30, 147-163	1.4	
96	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 264-266	18.8	3
95	Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease. <i>International Journal of Eating Disorders</i> , 2021 , 54, 2025-2030	6.3	1
94	Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India. <i>Microorganisms</i> , 2021 , 9,	4.9	1

93	Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?. <i>Gut</i> , 2021 , 70, 225-226	19.2	5
92	Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1444-1447	11.6	18
91	NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials. <i>Journal of Hepatology</i> , 2021 , 74, 241-242	13.4	0
90	Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?. <i>Gut Microbes</i> , 2021 , 13, 1-9	8.8	12
89	The contribution of bile acid metabolism to the pathogenesis of infection. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211017725	4.7	9
88	Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults. <i>Scientific Reports</i> , 2021 , 11, 5	4.9	5
87	Fecal Microbiota Transplantation: The Evolving Risk Landscape. <i>American Journal of Gastroenterology</i> , 2021 , 116, 647-656	0.7	14
86	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. <i>Lancet Regional Health - Europe, The</i> , 2021 , 9, 100181		5
85	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 684659	5.9	3
84	Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series. <i>American Journal of Hematology</i> , 2021 , 96, E461-E463	7.1	4
83	Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. <i>Hormones</i> , 2021 , 20, 209-211	3.1	9
82	Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?. <i>World Journal of Hepatology</i> , 2021 , 13, 2104-2112	3.4	1
81	Faecal microbiota transplantation for recurrent infection: An updated systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2020 , 29-30, 100642	11.3	31
80	A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague-Dawley Rats. <i>Journal of Proteome Research</i> , 2020 , 19, 3326-3339	5.6	18
79	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 430-432	18.8	82
78	A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. <i>Scientific Reports</i> , 2020 , 10, 4183	4.9	27
77	Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. <i>Scientific Reports</i> , 2020 , 10, 3895	4.9	11
76	Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, COVID-19: Immunology and treatment options§ Felsenstein, Herbert McNamara et al. <i>2020S Clinical Immunology</i> , 2020 , 218, 108542	9	7

75	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020 , 69, 1555-1563	19.2	57
74	Faecal microbiota transplantations and urinary tract infections - AuthorsReply. <i>Lancet, The</i> , 2020 , 395, 271	4.0	1
73	Letter: intestinal microbiota transfer-updating the nomenclature to increase acceptability. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1622-1623	6.1	2
72	S0650 Fecal Microbiota Transplantation Decolonizes <i>C. difficile</i> in Patients With Inflammatory Bowel Disease and Concomitant <i>C. difficile</i> Infection. <i>American Journal of Gastroenterology</i> , 2020 , 115, S326-S326	0.7	
71	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. <i>Immunology</i> , 2020 , 159, 167-177	7.8	35
70	High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2081-2090.e9	6.9	35
69	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. <i>PLoS ONE</i> , 2020 , 15, e0240400	3.7	24
68	P844 Higher proportions of genera and species in the Firmicutes phylum are associated with a healthy pouch compared with patients with chronic pouchitis. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S652-S652	1.5	
67	Letter: faecal microbiota transplantation for IBS. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 556-557	6.1	2
66	Letter: liver disease and COVID-19-not the perfect storm. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 572-574	6.1	3
65	The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820974914	4.7	25
64	Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent <i>Clostridioides difficile</i> Infection. <i>Gastroenterology</i> , 2020 , 159, 1982-1984	13.3	15
63	A Guide to the Gut Microbiome and its Relevance to Critical Care. <i>British Journal of Nursing</i> , 2020 , 29, 1106-1112	0.7	
62	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820946904	4.7	10
61	Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. <i>Future Microbiology</i> , 2020 , 15, 1173-1183	2.9	7
60	Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent infection and beyond: the contribution of gut microbial-derived metabolites. <i>Gut Microbes</i> , 2020 , 12, 1810531	8.8	12
59	In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. <i>Gut Microbes</i> , 2020 , 11, 51-62	8.8	13
58	Recurrent bacteraemia following variceal haemorrhage. <i>Gut</i> , 2020 , 69, 726-780	19.2	

57	Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 855-863.e2	6.9	87
56	7 The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation. <i>Gastroenterology</i> , 2019 , 156, S-2-S-3	13.3	2
55	The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284818822250	4.7	36
54	Faecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: SA five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: A Randomized Clinical Trials <i>Clinical Microbiology and Infection</i> , 2019 , 25, 912-913	9.5	2
53	Current and future pharmacological therapies for managing cirrhosis and its complications. <i>World Journal of Gastroenterology</i> , 2019 , 25, 888-908	5.6	24
52	Sa1924 Effect of Short Chain Fatty Acids on Gut-Brain Axis Using a Microglial Cell Model. <i>Gastroenterology</i> , 2019 , 156, S-455	13.3	2
51	Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1077-1085	6.1	21
50	Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. <i>American Journal of Gastroenterology</i> , 2019 , 114, 1071-1079	0.7	82
49	Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. <i>Liver International</i> , 2019 , 39, 967-975	7.9	13
48	Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent infection. <i>Gut</i> , 2019 , 68, 1791-1800	19.2	100
47	The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. <i>Lancet, The</i> , 2019 , 394, 420-431	4.0	145
46	Antibiotic therapy and outcome from immune-checkpoint inhibitors 2019 , 7, 287		48
45	Posters (Abstracts 289-348). <i>Hepatology</i> , 2019 , 70, 188-1382	11.2	10
44	Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease-authorsSreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1140-1141	6.1	
43	Liver Biopsy 2019 , 395-407		
42	837 Short Chain Fatty Acid Profiles Are Altered by Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection. <i>American Journal of Gastroenterology</i> , 2019 , 114, S484-S485	0.7	
41	Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819891038	4.7	11
40	185 Evaluating Dynamics of Bile Acid Metabolism to Predict Recurrence of Clostridioides difficile Infection. <i>American Journal of Gastroenterology</i> , 2019 , 114, S113-S113	0.7	0

39	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019 , 68, 2111-2121	19.2	169
38	Effective fecal microbiota transplantation for recurrent <i>Clostridioides difficile</i> infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway. <i>Gut Microbes</i> , 2019 , 10, 142-148	8.8	24
37	Current and future targets for faecal microbiota transplantation. <i>Human Microbiome Journal</i> , 2019 , 11, 100045	5.6	4
36	Gastrointestinal: Duodenal variceal bleeding secondary to thrombophilia-related portal vein thrombosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 336	4	
35	Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease. <i>Methods</i> , 2018 , 149, 49-58	4.6	44
34	The use of faecal microbiota transplant as treatment for recurrent or refractory infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. <i>Gut</i> , 2018 , 67, 1920-1941	19.2	153
33	infection and antibiotic-associated diarrhoea. <i>Clinical Medicine</i> , 2018 , 18, 237-241	1.9	45
32	Letter: improvements in mental health after faecal microbiota transplantation-an underexplored treatment-related benefit?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1562-1563	6.1	2
31	Meeting update: faecal microbiota transplantation--bench, bedside, courtroom?. <i>Frontline Gastroenterology</i> , 2018 , 9, 45-48	2.6	3
30	1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S353-S354	1	78
29	Inhibiting Growth of <i>Clostridioides difficile</i> by Restoring Valerate, Produced by the Intestinal Microbiota. <i>Gastroenterology</i> , 2018 , 155, 1495-1507.e15	13.3	70
28	The implementation of omics technologies in cancer microbiome research. <i>Ecancermedicalscience</i> , 2018 , 12, 864	2.7	8
27	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2018 , 53, 1051-1058	2.4	6
26	Fecal microbiota and bile acid interactions with systemic and adipose tissue metabolism in diet-induced weight loss of obese postmenopausal women. <i>Journal of Translational Medicine</i> , 2018 , 16, 244	8.5	44
25	The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridium difficile</i> infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. <i>Journal of Hospital Infection</i> , 2018 , 100 Suppl 1, S1-S31	6.9	23
24	Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. <i>Hepatology</i> , 2018 , 68, 1205	11.2	4
23	25 - Microbiome and Metabolic Markers of <i>Clostridium Difficile</i> Recurrence. <i>Gastroenterology</i> , 2018 , 154, S-8-S-9	13.3	2
22	Anticoagulation in chronic liver disease. <i>Journal of Hepatology</i> , 2017 , 66, 1313-1326	13.4	36

21	Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes. <i>Gastroenterology</i> , 2017 , 152, S47	13.3	2
20	Comparative epidemiology of Clostridium difficile infection: England and the USA. <i>International Journal for Quality in Health Care</i> , 2017 , 29, 785-791	1.9	13
19	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. <i>Hepatology</i> , 2017 , 66, 1354-1355	11.2	13
18	Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1452-1454	4.4	22
17	National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK. <i>Journal of Hospital Infection</i> , 2017 , 95, 444-445	6.9	13
16	Global Metabolic Stress of Isoeffort Continuous and High Intensity Interval Aerobic Exercise: A Comparative H NMR Metabonomic Study. <i>Journal of Proteome Research</i> , 2016 , 15, 4452-4463	5.6	22
15	OC-040 National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom. <i>Gut</i> , 2016 , 65, A23.2-A24	19.2	
14	PWE-094 Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?. <i>Gut</i> , 2016 , 65, A184.2-A184	18.2	
13	Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces. <i>Analytical Chemistry</i> , 2016 , 88, 4661-8	7.8	97
12	Weight loss in a man from West Africa. <i>S. stercoralis</i> hyperinfection. <i>Gut</i> , 2015 , 64, 1846, 1888	19.2	1
11	Letter: depression and the use of anti-depressants in patients with chronic liver disease or liver transplantation - authorsSreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 914-5	6.1	1
10	Monitoring the Response of the Human Urinary Metabolome to Brief Maximal Exercise by a Combination of RP-UPLC-MS and (1)H NMR Spectroscopy. <i>Journal of Proteome Research</i> , 2015 , 14, 4610-22	5.6	32
9	Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. <i>Analytical Chemistry</i> , 2015 , 87, 9662-70	7.8	120
8	Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015 , 108, 355-9	2.7	11
7	Obstacles to establishing an NHS faecal transplant programme. <i>BMJ, The</i> , 2015 , 351, h6043	5.9	6
6	Aspartame sensitivity? A double blind randomised crossover study. <i>PLoS ONE</i> , 2015 , 10, e0116212	3.7	7
5	Case 25-2014: A man with ulcerative colitis and bloody diarrhea. <i>New England Journal of Medicine</i> , 2014 , 371, 1848-9	59.2	4
4	Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature. <i>BMC Gastroenterology</i> , 2014 , 14, 60	3	5

3	Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 880-92	6.1	72
2	Shoulder pain and dysphagia with an unexpected cause. <i>BMJ Case Reports</i> , 2011 , 2011,	0.9	0
1	Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use. <i>European Medical Journal (Chelmsford, England)</i> ,94-100	7.5	